Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain Patricia de Sequera, Ramón Bover, Yoana Ivanova-Markova, Alexandra Ivanova, Almudena González-Domínguez, Marta Valls, Verónica Campos

Oral paricalcitol as antiproteinuric agent in chronic kidney disease Alberto de Lorenzo, Laura Salanova, Andrew S. Bomback, María Moya, Maria Moya, Francisco Coronel, Carmen Bernis, José A. Sánchez-Tomero, José Antonio Sánchez-Tomero, Vicente Álvarez

The renin–angiotensin–aldosterone system blockade in patients with advanced diabetic kidney disease Sheila Bermejo, Carles Oriol García, Eva Rodríguez, Clara Barrios, Sol Otero, Sergi Mojal, Julio Pascual, María José Soler